BioTuesdays

Maxim starts Fennec Pharma at buy: PT $12

Maxim Group initiated coverage of Fennec Pharmaceuticals (NASDAQ:FENC) with a “buy” rating and price target of $12. The stock closed at $6.27 on April 16. Fennec is developing PEDMARK, a unique formulation of...

SVB Leerink starts Lava Therapeutics at OP; PT $26

SVB Leerink launched coverage of Lava Therapeutics N.V. (NASDAQ:LVTX) with an “outperform” rating and $26 price target. The stock closed at $15 on April 16. Lava is at the leading edge of therapeutically targeting the...

111 inc logo

Citi transfers coverage of 111 Inc. with $16 PT

Citi Research transferred coverage of 111 Inc. (NASDAQ:YI) to Zoe Bian from Cui Cui, retaining a “buy/high risk” rating and price target of $16. Citi recently raised its price target to $16 from $12. The stock closed at...

examen-logo

Canaccord starts Exagen at buy; PT $25

Canaccord Genuity launched coverage of Exagen (NASDAQ:XGN) with a “buy” rating and $25 price target. The stock closed at $16.69 on April 14. Analyst Max Masucci writes that Exagen provides a broad range of tests used to...

Connect-Logo

SVB Leerink starts Connect Biopharma at OP; PT $32

SVB Leerink launched coverage of Connect Biopharma Holdings (NASDAQ:CNTB) with an “outperform” rating and price target of $32. The stock closed at $17.05 on April 12.  Connect is a clinical-stage biotech headquartered...

Gain-Logo

BTIG starts Gain Therapeutics at buy; PT 30

BTIG initiated coverage of Gain Therapeutics (NASDAQ:GANX) with a “buy” rating and $30 price target. The stock closed at $13.98 on April 9. Gain is a computational and medicinal chemistry-based biotechnology company...

Diagnos-Logo

Echelon pegs DIAGNOS as Q2 “top picks portfolio”

Echelon Capital Markets added DIAGNOS (TSXV:ADK) to its second quarter “top picks portfolio.” Analyst Stefan Quenneville rates the stock as “speculative buy” with a price target of 85 cents. The stock was quoted at 53...

Mesoblast Logo

Maxim ups Mesoblast to buy from hold; PT $18

Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...

Prometheus-Logo

Analysts start Prometheus Biosciences at OP and buy

Analysts for Stifel and SVB Leerink initiated coverage of Prometheus Biosciences (NASDAQ:RXDX) with “outperform” and “buy” ratings, respectively, and price targets of $25 and $34, respectively. The stock closed at $19...

Cantor starts Longboard Pharma at OW; PT $32

Cantor Fitzgerald launched coverage of Longboard Pharmaceuticals (NASDAQ:LBPH) with an “overweight” rating and $32 price target. The stock closed at $16.67 on April 5. Longboard was spun out of Arena Pharmaceuticals...

EyeGate Pharmaceuticals

AGP cuts EyeGate Pharma PT to $10.25 from $16.75

Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...

Lineage-Cell-Therapeutics-Logo

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...

Amryt-Logo

Maxim starts Amryt Pharma at buy; PT $27

Maxim Group launched coverage of Amryt Pharma plc (NASDAQ, AIM:AMYT) with a “buy” rating and $27 price target. The stock closed at $13.84 on March 30. Amryt is a commercial rare disease company globally marketing...

CareRX-Logo

Echelon starts CareRx at buy; PT $7.25 (Canadian)

Echelon Capital Markets initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and price target of $7.25 (Canadian). The stock closed at $5.39 on March 29. CareRx is Canada’s leading pharmacy services provider for...

Cantor starts PAVmed at OW; PT $8

Cantor Fitzgerald initiated coverage of PAVmed (NASDAQ:PAVM) with an “overweight” rating and price target of $8. The stock closed at $3.93 on March 29. The company employs a unique business model that emphasizes capital...

Aytu-logo

Cantor starts Aytu BioPharma at OW; PT $11

Cantor Fitzgerald launched coverage of Aytu BioPharma (NASDAQ:AYTU) with an “overweight” rating and $11 price target. The stock closed at $7.49 on March 29. “Through a strategy of in-licensing and acquisition-based...